Results 1 to 10 of about 19,685 (117)
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases [PDF]
BMC Nephrology, 2020 Background Dipeptidyl peptidase-4 (DPP-4) is a serine protease that inhibits the degradation of glucagon-like peptide 1. DPP-4 inhibitors are used worldwide to treat type 2 diabetes mellitus and were recently shown to have pleiotropic effects such as ...
Ayano Kubo +6 more
doaj +2 more sources
Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea [PDF]
Kidney Research and Clinical Practice, 2021 Background Dipeptidyl peptidase-4 (DPP-4) inhibitor has been reported to have kidney-protective benefits. To elucidate how antidiabetic agents prevent diabetic kidney disease progression, it is important to investigate their effect on the kidney ...
Nam-Jun Cho +9 more
doaj +1 more source
Kidney & Blood Pressure Research, 2021 Introduction: Dipeptidyl peptidase-4 (DPP-4) has been hypothesized to improve responsiveness to erythropoiesis-stimulating agent (ESA). We aimed to describe the trend in DPP-4 inhibitor prescription patterns and assess the association between DPP-4 ...
Takeshi Hasegawa +7 more
doaj +1 more source
Frontiers in Public Health, 2021 Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl
Wei-Hao Hsu +13 more
doaj +1 more source
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]
Diabetes & Metabolism Journal, 2022 Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong +3 more
doaj +1 more source
A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. [PDF]
PLoS ONE, 2015 Myocarditis is a critical inflammatory disorder which causes life-threatening conditions. No specific or effective treatment has been established. DPP-4 inhibitors have salutary effects not only on type 2 diabetes but also on certain cardiovascular ...
Hiroyuki Hirakawa +7 more
doaj +1 more source
Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis [PDF]
Endocrinology and Metabolism, 2023 Background The effects of dipeptidyl peptidase 4 (DPP-4) inhibitors over the course of long-term treatment remain unclear, and concerns have been raised regarding the role of DPP-4 inhibitors in carcinogenesis in the pancreas.
Mee Kyoung Kim +3 more
doaj +1 more source
Frontiers in Endocrinology, 2020 Objective: We recently observed a greater increase in plasma levels of bioactive glucose-dependent insulinotropic polypeptide (GIP) than glucagon-like peptide 1 (GLP-1) using the receptor-mediated bioassays in the subjects with normal glycemic tolerance (
Tsuyoshi Yanagimachi +7 more
doaj +1 more source
DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells. [PDF]
PLoS ONE, 2014 Diabetic nephropathy is a common causative factor of chronic kidney disease (CKD). DPP-4 inhibitor has the ability to improve kidney function and renal microvasculature.
Wei-Jie Wang +4 more
doaj +1 more source
Journal of Pharmacological Sciences, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties.
Akari Nagamine +8 more
doaj +1 more source